Latest Period
Q2 2026
Security Snapshot
ImmunityBio, Inc. - Common Stock, par value $0.0001 per share (IBRX) Institutional Ownership
CUSIP: 45256X103
13F Institutional Holders and Ownership History from Q1 2019 to Q2 2026
Institutions Reporting
399
Shares (Excl. Options)
200,688,033
Price
$8.76
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- IBRX on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 200,688,033
- Total 13F value
- $1,756,060,401
- Portfolio coverage rank
- 0%
- Share change
- +22,121,722
- Value change
- +$200,288,275
- Number of holders
- 399
- Shares outstanding
- 1,150,491,181
- SEC-reported price per share
- $7.45
- Insider filing price
- $7.45
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- IBRX - ImmunityBio, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 45256X103.
- 399 institutions reported positions in Q2 2026.
- 1 significant owner is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 382 to 399 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $1,362,861,564 to $1,756,060,401.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 399 institutions filings for Q2 2026.
Security key
45256X103
Latest holder period
Q2 2026
13F holders
399
13D/G owners
1
CIK / CUSIP context first
Open Q2 2026 holders
IBRX full holder history
ImmunityBio, Inc. SEC filings
ImmunityBio, Inc. company facts
ImmunityBio, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 45256X103:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
1
Security
IBRX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Cambridge Equities, LP | 65% | -2.3% | $5,807,587,440 | -$453,152 | 745,518,285 | -0.01% | Patrick Soon-Shiong | 31 Jul 2026 |
As of 30 Jun 2026, 399 institutional investors reported holding 200,688,033 shares of ImmunityBio, Inc. - Common Stock, par value $0.0001 per share (IBRX). This represents 17% of the company’s total 1,150,491,181 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
14%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 3% | 34,083,262 | +29% | 0% | $298,398,958 |
| STATE STREET CORP | 1.9% | 21,398,438 | +21% | 0.01% | $187,343,325 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.6% | 17,863,911 | +9.4% | 0.01% | $156,398,541 |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.4% | 15,691,579 | +3.7% | 0% | $137,379,774 |
| D. E. Shaw & Co., Inc. | 1% | 11,551,019 | -8.1% | 0.06% | $101,129,171 |
| TWO SIGMA INVESTMENTS, LP | 0.96% | 11,097,106 | +153% | 0.07% | $97,155,163 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.86% | 9,847,896 | +23% | 0% | $86,230,624 |
| MILLENNIUM MANAGEMENT LLC | 0.48% | 5,579,793 | +293% | 0.03% | $48,851,088 |
| NORTHERN TRUST CORP | 0.31% | 3,565,248 | +42% | 0% | $31,213,746 |
| MORGAN STANLEY | 0.3% | 3,432,678 | -15% | 0% | $30,053,096 |
| GOLDMAN SACHS GROUP INC | 0.28% | 3,234,277 | -0.09% | 0% | $28,316,099 |
| UBS Group AG | 0.28% | 3,195,728 | +8.5% | 0% | $27,978,598 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.25% | 2,888,607 | +17% | 0% | $25,289,754 |
| Woodline Partners LP | 0.22% | 2,500,189 | -27% | 0.07% | $21,889,155 |
| SEB Asset Management AB | 0.21% | 2,447,150 | 0% | 0.08% | $21,424,757 |
| VANGUARD FIDUCIARY TRUST CO | 0.21% | 2,412,338 | +14% | 0% | $21,120,019 |
| BANK OF AMERICA CORP /DE/ | 0.19% | 2,184,489 | -11% | 0% | $19,125,201 |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | 0.15% | 1,721,902 | -41% | 0.06% | $15,075,252 |
| FEDERATED HERMES, INC. | 0.15% | 1,713,200 | +24% | 0.02% | $14,999,066 |
| ROYAL BANK OF CANADA | 0.13% | 1,542,717 | +3.8% | 0% | $13,506,000 |
| JPMORGAN CHASE & CO | 0.13% | 1,450,180 | -2.6% | 0% | $12,871,781 |
| Bank of New York Mellon Corp | 0.11% | 1,314,760 | +58% | 0% | $11,510,727 |
| FIRST TRUST ADVISORS LP | 0.11% | 1,214,667 | 0.01% | $10,634,409 | |
| Cetera Investment Advisers | 0.1% | 1,140,476 | +20% | 0.01% | $9,984,867 |
| Sound Capital Solutions LLC | 0.1% | 1,120,808 | 0% | 2.3% | $9,812,674 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
30
Latest
Q2 2026
Rows shown
1-25 of 30
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 200,688,033 | $1,756,060,401 | +$200,288,275 | $8.76 | 399 |
| 2026 Q1 | 178,067,821 | $1,362,861,564 | +$100,105,542 | $7.67 | 382 |
| 2025 Q4 | 167,498,886 | $331,914,340 | +$45,128,854 | $1.98 | 267 |
| 2025 Q3 | 149,650,186 | $368,148,509 | +$61,432,781 | $2.46 | 258 |
| 2025 Q2 | 124,100,473 | $327,790,828 | +$117,120,227 | $2.64 | 236 |
| 2025 Q1 | 79,547,067 | $239,251,849 | -$5,452,987 | $3.01 | 205 |
| 2024 Q4 | 82,639,855 | $211,622,425 | +$33,803,467 | $2.56 | 193 |
| 2024 Q3 | 68,558,924 | $255,147,599 | +$21,750,911 | $3.72 | 172 |
| 2024 Q2 | 61,630,296 | $389,584,078 | -$21,451,973 | $6.32 | 188 |
| 2024 Q1 | 66,215,691 | $355,583,288 | +$50,300,460 | $5.37 | 157 |
| 2023 Q4 | 57,525,605 | $288,814,721 | +$55,491,609 | $5.02 | 141 |
| 2023 Q3 | 49,844,823 | $84,098,555 | +$17,530,681 | $1.69 | 128 |
| 2023 Q2 | 38,816,393 | $107,856,591 | -$8,601,646 | $2.78 | 108 |
| 2023 Q1 | 46,154,939 | $83,993,343 | -$34,886,181 | $1.82 | 141 |
| 2022 Q4 | 49,991,144 | $253,404,020 | +$54,026,855 | $5.07 | 134 |
| 2022 Q3 | 39,497,245 | $196,456,912 | +$32,509,458 | $4.97 | 117 |
| 2022 Q2 | 33,071,782 | $123,053,543 | -$11,174,770 | $3.72 | 124 |
| 2022 Q1 | 35,583,839 | $199,726,649 | +$5,888,206 | $5.61 | 135 |
| 2021 Q4 | 34,419,957 | $209,314,595 | +$13,197,046 | $6.08 | 127 |
| 2021 Q3 | 31,920,475 | $310,877,791 | +$41,850,403 | $9.74 | 118 |
| 2021 Q2 | 27,315,269 | $390,084,556 | +$155,924,275 | $14.28 | 115 |
| 2021 Q1 | 15,930,587 | $378,240,945 | +$377,213,945 | $23.74 | 112 |
| 2020 Q4 | 100 | $1,000 | $10.00 | 1 | |
| 2020 Q3 | 100 | $1,000 | $10.00 | 1 | |
| 2020 Q2 | 100 | $1,000 | $10.00 | 1 |